-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The efficacy of nab-paclitaxel as neoadjuvant chemotherapy in patients with HER2- breast cancer is unclear
breast cancer
This study retrospectively analyzed patients with HER2-negative breast cancer who underwent neoadjuvant therapy and surgery from May 2016 to April 2018
The study included 159 patients, including 79 in the nab-paclitaxel group and 80 in the docetaxel group
The ORRs of the albumin-paclitaxel group and the docetaxel group were 89.
Albumin - paclitaxel and docetaxel ORR group was 89.
Efficacy assessment
After subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.
After subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.
Efficacy assessment subgroup analysis
After a median follow-up of 47 months, 33 of 159 patients (20.
Taken together, the study demonstrated a higher pCR rate with nab-paclitaxel compared with docetaxel, especially in patients with triple-negative or node-negative breast cancer
Studies have shown a higher pCR rate with nab-paclitaxel compared with docetaxel, especially in patients with triple-negative or node-negative breast cancer
Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W and Wang HB (2022) Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W and Wang HB (2022) Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Front.
Oncol .
11:760655.
doi: 10.
3389/fonc.
2021.
760655 Comment
here
